Compositions and methods related to anti-CD19 antibody drug conjugates

The present disclosure relates to antibody-drug conjugates (ADCs) wherein one or more active agents are conjugated to an anti-CD19 antibody through a linker. The linker may comprise a unit that covalently links active agents to the antibody. The disclosure further relates to monoclonal antibodies an...

Full description

Saved in:
Bibliographic Details
Main Authors Ryu, Hyun Min, Park, Yun Hee, Oh, Yeong Soo, Kim, Sung Min, Kim, Hyoung Rae, Kim, Yong Zu, Deehan, Maureen, Fischer, Nicolas, Oh, Ji Hye, Song, Ho Young, Chae, Jeiwook
Format Patent
LanguageEnglish
Published 28.11.2023
Subjects
CHEMISTRY
DERIVATIVES THEREOF
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
NUCLEIC ACIDS
NUCLEOSIDES
NUCLEOTIDES
ORGANIC CHEMISTRY
PEPTIDES
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SUGARS
Online AccessGet full text

Cover

More Information
Summary:The present disclosure relates to antibody-drug conjugates (ADCs) wherein one or more active agents are conjugated to an anti-CD19 antibody through a linker. The linker may comprise a unit that covalently links active agents to the antibody. The disclosure further relates to monoclonal antibodies and antigen binding fragments, variants, multimeric versions, or bispecifics thereof that specifically bind CD19, as well as methods of making and using these anti-CD19 antibodies and antigen-binding fragments thereof in a variety of therapeutic, diagnostic and prophylactic indications.
Bibliography:Application Number: US201916408002